Product Code: RP-ID-10324792 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10324792
Market Overview:
Impact analysis of COVID-19 on Cancer Screening Global Market Outlook 2027
Cancer Screening Market Analysis – 2019-2027
According to the World Health Organization, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018.Cancer screening tests are diagnostic procedures that are done in order to identify cancer in the body and therefore reduce the number of people who develop cancer or reach the later stages of cancer where it becomes untreatable. These tests can help to detect cancer at its early stages, where it may be easier to treat. The market for cancer screening is anticipated to grow at a significant CAGR of around 9.67% over the forecast period, i.e., 2020-2027.
The market is segmented by diagnostic methods, by cancer, by end user and by region. Based on the diagnostic methods, the market for cancer screening is segmented into genetic tests, instrument based tests and platform based tests. Out of these, the segment for instrument based tests is is anticipated to attain a market size of around USD 177,978 million by the year 2027 and is projected to grow with a significant CAGR over the forecast period. This segment is further divided into imaging tests, endoscopy procedures and biopsy, out of which, the segment for imaging tests is predicted to hold the leading share in the market on account of rising demand for minimally invasive procedures globally.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to hold the leading share over the forecast period. The growth in the region can be attributed to the increase in investments towards healthcare from government and private entities in order to maintain the highest quality of care offered in healthcare facilities. Further, the market in Asia Pacific region is anticipated to grow with the highest CAGR of 11.12% over the forecast period on account of demand for new and improved technology and treatment methods from China. With the rising availability of advanced healthcare in Asia Pacific along with growing number of manufacturers investing in countries such as China, Japan, & India, the demand for cancer screening products in this region is estimated to witness a rapid growth in the coming years.
Some of the key industry leaders in the global cancer screening market are Siemens Healthineers AG, GE Healthcare, Abbott, F. Hoffmann-La Roche Ltd., Olympus Corporation, FUJIFILM Corporation, Agilent Technologies, Inc. and Thermo Fisher Scientific.
Related Reports
Proof of Quality & Reliability
